Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: The SENIOR study

European Urology

Volumn 64, Issue 1, 2013, Pages 74-81

  Wagg, Adrian ^a   Dale, Mark ^b   Tretter, Reiner ^c   Stow, Bridget ^d   Compion, Gerhard ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MAC Clinical Research   (United Kingdom)

^c Astellas Pharma Global Development   (Netherlands)

^d Astellas Pharma Europe Ltd   (United Kingdom)

Author keywords

Mild cognitive impairment; Overactive bladder; Oxybutynin; Solifenacin

Indexed keywords

OXYBUTYNIN; PLACEBO; SOLIFENACIN;

AGED; ARTICLE; ATTENTION; BACKACHE; BALANCE DISORDER; BLURRED VISION; CLINICAL ARTICLE; COGNITION; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EPISODIC MEMORY; EYE DISEASE; FEMALE; HEART DISEASE; HUMAN; MALE; MENTAL DISEASE; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY; NAUSEA; OROPHARYNX PAIN; OUTCOME ASSESSMENT; POLLAKISURIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SECONDARY ANALYSIS; SKIN DISEASE; THRUSH; TIME TO MAXIMUM PLASMA CONCENTRATION; WORKING MEMORY; XEROSTOMIA;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANALYSIS OF VARIANCE; ATTENTION; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GREAT BRITAIN; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MANDELIC ACIDS; MEMORY; MILD COGNITIVE IMPAIRMENT; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; RISK FACTORS; TETRAHYDROISOQUINOLINES; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; UROLOGICAL AGENTS;

EID: 84878829234     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.01.002     Document Type: Article

References (30)

1. P. Abrams, W. Artibani, L. Cardozo, R. Dmochowski, P. van Kerrebroeck, and P. Sand Reviewing the ICS 2002 terminology report: the ongoing debate Neurourol Urodyn 28 2009 287
2. W.F. Stewart, J.B. Van Rooyen, and G.W. Cundiff Prevalence and burden of overactive bladder in the United States World J Urol 20 2003 327 336
3. K.S. Coyne, C.C. Sexton, V. Vats, C. Thompson, Z.S. Kopp, and I. Milsom National community prevalence of overactive bladder in the United States stratified by sex and age Urology 77 2011 1081 1087
4. A. Wagg Managing special populations: the elderly Eur Urol Suppl 5 2006 866 870
5. R.R. Dmochowski, and A. Gomelsky Update on the treatment of overactive bladder Curr Opin Urol 21 2011 286 290
6. M. Chancellor, and T. Boone Anticholinergics for overactive bladder therapy: central nervous system effects CNS Neurosci Ther 18 2012 167 174
7. A. Wagg The cognitive burden of anticholinergics in the elderly-implications for the treatment of overactive bladder Eur Urol Rev 7 2012 42 49
8. B.D. Zipser, C.E. Johanson, and L. Gonzalez Microvascular injury and blood-brain barrier leakage in Alzheimer's disease Neurobiol Aging 28 2007 977 986
9. J.M. Starr, J. Wardlaw, K. Ferguson, A. MacLullich, I.J. Deary, and I. Marshall Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging J Neurol Neurosurg Psychiatry 74 2003 70 76
10. A. Minagar, and J.S. Alexander Blood-brain barrier disruption in multiple sclerosis Mult Scler 9 2003 540 549
11. A. Wagg Treating overactive bladder in the elderly Can Urol Assoc J 5 Suppl 2 2011 S149 S151
12. K.A. Wesnes, C. Edgar, R.N. Tretter, and J. Bolodeoku Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg Expert Opin Drug Saf 8 2009 615 626
13. I.R. Katz, L.P. Sands, W. Bilker, S. DiFilippo, A. Boyce, and K. D'Angelo Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride J Am Geriatr Soc 46 1998 8 13
14. G. Kay, T. Crook, and L. Rekeda Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects Eur Urol 50 2006 317 326
15. R.B. Lipton, K. Kolodner, and K. Wesnes Assessment of cognitive function of the elderly population: effects of darifenacin J Urol 173 2005 493 498
16. B. Winblad, K. Palmer, and M. Kivipelto Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment J Intern Med 256 2004 240 246
17. M.F. Folstein, S.E. Folstein, and P.R. McHugh "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
18. J.I. Sheikh, and J.A. Yesavage Geriatric depression scale (GDS). Recent evidence and development of a shorter version T.L. Brink, Clinical Gerontology: A Guide to Assessment and Intervention 1986 Haworth Press New York, NY 165 173
19. K.A. Wesnes, C. Garratt, M. Wickens, A. Gudgeon, and S. Oliver Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers Br J Clin Pharmacol 49 2000 110 117
20. K.A. Wesnes The value of assessing cognitive function in drug development Dialogues Clin Neurosci 2 2000 183 202
21. R.C. Petersen Clinical practice. Mild cognitive impairment N Engl J Med 364 2011 2227 2234
22. K.A. Bottiggi, J.C. Salazar, and L. Yu Long-term cognitive impact of anticholinergic medications in older adults Am J Geriatr Psychiatry 14 2006 980 984
23. C. Fox, K. Richardson, and I.D. Maidment Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study J Am Geriatr Soc 59 2011 1477 1483
24. L. Han, J.V. Agostini, and H.G. Allore Cumulative anticholinergic exposure is associated with poor memory and executive function in older men J Am Geriatr Soc 56 2008 2203 2210
25. S.M. Jakobsen, H. Kersten, and E. Molden Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay J Am Geriatr Soc 59 2011 501 505
26. E. Callegari, B. Malhotra, and P.J. Bungay A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder Br J Clin Pharmacol 72 2011 235 246
27. T.E. Lackner, J.F. Wyman, T.C. McCarthy, M. Monigold, and C. Davey Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence J Am Geriatr Soc 56 2008 862 870
28. K.M. Sink, J. Thomas III, H. Xu, B. Craig, S. Kritchevsky, and L.P. Sands Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes J Am Geriatr Soc 56 2008 847 853
29. A.T. Isik, and E. Bozoglu Acetylcholinesterase inhibition and insulin resistance in late onset Alzheimer's disease Int Psychogeriatr 21 2009 1127 1133
30. R. Sakakibara, T. Ogata, and T. Uchiyama How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist J Am Geriatr Soc 57 2009 1515 1517